Allergic History and Anaphylaxis in COVID-19 Vaccines: A Disproportionality Analysis in the FDA Vaccine Adverse Event Reporting System

被引：0
|
作者：
Giunchi, V. [1 ]
Niero, A. [2 ]
Bartolucci, M. [3 ]
Fusaroli, M. [1 ]
Romio, M. S. [4 ]
Rossi, L. [4 ]
Pulvirenti, L. [4 ]
Savini, D. [4 ]
Sangiorgi, E. [5 ]
Luxi, N.
Trifiro, G. [6 ]
Poluzzi, E. [1 ]
Raschi, E. [1 ]
Sacripanti, C. [4 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy
[2] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy
[3] Univ Bologna, Dept Stat Sci, Bologna, Italy
[4] AUSL Bologna, Dept Pharmaceut, Bologna, Italy
[5] AUSL Ferrara, Dept Pharmaceut, Ferrara, Italy
[6] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy
来源：
DRUG SAFETY | 2022年 / 45卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
P095
引用
收藏
页码：1308 / 1308
页数：1
相关论文
共 50 条
  • [31] Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database
    Shah, Divya
    Stone, Cosby
    Rukasin, Christine
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB77 - AB77
  • [32] Usefulness of Vaccine Adverse Event Reporting System for Machine-Learning Based Vaccine Research: A Case Study for COVID-19 Vaccines
    Flora, James
    Khan, Wasiq
    Jin, Jennifer
    Jin, Daniel
    Hussain, Abir
    Dajani, Khalil
    Khan, Bilal
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [33] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [34] A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen
    Du, Yikuan
    Guo, Zhuoming
    Xu, Bijun
    Yang, Yujia
    Hu, Mianda
    Hu, Yanghui
    Yang, Yurong
    Zhang, Mengting
    Wang, Zhenjie
    Guo, Xiaochun
    Huang, Yixing
    Zhu, Jinfeng
    Zhang, Weichui
    Yang, Chun
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [35] A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
    Li, Huqun
    Wang, Chongshu
    Deng, Aiping
    Guo, Cuilian
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
    Nyankerh, Cyril N. A.
    Boateng, Akosua K.
    Appah, Mary
    [J]. VACCINES, 2022, 10 (06)
  • [37] Changes in vaccine adverse event reporting system reports during the COVID-19 pandemic
    Hogue, Kelly
    Forrester, Mathias
    [J]. CLINICAL TOXICOLOGY, 2021, 59 (11) : 1046 - 1046
  • [38] Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System
    Huang, Liting
    Liu, Ying
    Li, Huijun
    Huang, Weicun
    Geng, Ruirui
    Tang, Zaixiang
    Jiang, Yiguo
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (09): : 1946 - 1952
  • [39] Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
    Wang, Feifei
    Zhou, Bingfeng
    Sun, Hongwei
    Wu, Xinan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [40] Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database
    Papazisis, G.
    Siafis, S.
    Cepatyte, D.
    Giannis, D.
    Stamoula, E.
    Tzachanis, D.
    Egberts, T.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (19) : 6003 - 6012
12345